This study is currently not recruiting participants.
A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) plus Sorafenib in patients with Unresectable Hepatocellular Carcinoma (HCC)
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study.
The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to determine the efficacy and associated toxicities in the treatment of liver cancer.
Detailed description of study
The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to determine the efficacy and associated toxicities in the treatment of liver cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Liver Cancer
Age:
18 years - 100 years
Gender: All
Updated on
18 Mar 2014.
Study ID: 1211009970
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
